Chunghwa Chemical Synthesis & Biotech Co Ltd
TWSE:1762
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Chunghwa Chemical Synthesis & Biotech Co Ltd
Research & Development
Chunghwa Chemical Synthesis & Biotech Co Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Chunghwa Chemical Synthesis & Biotech Co Ltd
TWSE:1762
|
Research & Development
-NT$168.3m
|
CAGR 3-Years
12%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-2%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Research & Development
-NT$401m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-1%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Research & Development
-NT$497.3m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-4%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Research & Development
-NT$986.7m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-13%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Research & Development
-NT$257.7m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-1%
|
|
|
C
|
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
|
Research & Development
-NT$650.5m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
Chunghwa Chemical Synthesis & Biotech Co Ltd
Glance View
Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the manufacture, research and development of active pharmaceutical ingredients (API). The company is headquartered in Taipei, New Taipei. The company went IPO on 2009-12-10. The firm's biotechnology products include pravastatin, rapamycin, tacrolimus, everolimus, mycophenolate mofetil, mycophenolic acid sodium and others. Its non-biotechnology products include methocarbamol, guaifenesin, trandolapril, fluconazole, olopatadine, dexbromopheniramine maleate and glipizide, among others. Its products are applied in the manufacture of drugs for treatment of cough, diabetes, cardiovascular diseases, high blood pressure and immune system diseases. The firm distributes its products within domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.
See Also
What is Chunghwa Chemical Synthesis & Biotech Co Ltd's Research & Development?
Research & Development
-168.3m
TWD
Based on the financial report for Dec 31, 2025, Chunghwa Chemical Synthesis & Biotech Co Ltd's Research & Development amounts to -168.3m TWD.
What is Chunghwa Chemical Synthesis & Biotech Co Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
-2%
Over the last year, the Research & Development growth was 18%. The average annual Research & Development growth rates for Chunghwa Chemical Synthesis & Biotech Co Ltd have been 12% over the past three years , 5% over the past five years , and -2% over the past ten years .
